TSTickerStarGet alerts

APUS 10-Q filed 2026-11-16 | Key takeaways

APUS filed its 10-Q; the most relevant disclosure change is expanded Discontinued operations and deconsolidation: Lokahi Therapeutics Inc. was deconsolidated on July 14, 2026 upon merger with Glucotrack, Inc.; company received 37,884 Glucotrack common shares and rights to 2,269,100 Series A preferred shares (as converted), measured at $962,935 total fair value; gain on de. Customer concentration: Two customers (Customer A and Customer B) represented 100% of revenue; Two customers represented 100% of accounts_rec...

Share this story

Key takeaways

  • Digital assets: Company holds $142.4 million in digital assets (93% of total assets), consisting of Bitcoin ($92.7 million, 65%), NILA tokens ($49.7 million, 35%), with Bitcoin price rising from $58,416 at June 30 to $83,780 at September 30.

  • Discontinued BioBusiness: Lokahi deconsolidated July 14, 2026 upon merger with Glucotrack; company received 37,884 Glucotrack common shares and rights to 2.3 million Series A preferred shares, recorded at $252,230 fair value after $710,705 Q3 loss.

  • Convertible note: $425,000 of principal converted to 305,002 shares at $1.3934 per share in September 2026; remaining principal of $10.5 million matures December 8, 2026 with forbearance expired June 30, 2026.

  • Going concern: Cash of only $17,912 as of September 30, 2026; substantial doubt exists about ability to continue as going concern within one year of filing date.

  • Customer concentration: Two customers account for 100% of Q3 and nine-month 2026 revenue and all accounts receivable ($2.48 million).

Key metrics

Total revenueQ3 2026
$2,898,899N/A (no revenue in Q3 2025)
Software development servicesQ3 2026
$2,480,000N/A
Digital asset yield incomeQ3 2026
$418,899N/A
Income from continuing operationsQ3 2026
$25,833,838vs $62,984 in Q3 2025
Net incomeQ3 2026
$33,646,166vs net loss of $1,781,255 in Q3 2025
Net lossNine months 2026
($21,586,816)vs net loss of $4,845,845 in nine months 2025
Basic EPSQ3 2026
$19.13vs ($1.42) in Q3 2025
Diluted EPSQ3 2026
$7.68vs ($1.42) in Q3 2025

Customer concentration

Two customers (Customer A and Customer B)Q3 2026 and nine months ended September 30, 2026
100%Share of revenue
Two customersSeptember 30, 2026
100%Share of accounts receivable

Disclosure changes

  • Discontinued operations and deconsolidation

    Lokahi Therapeutics Inc. was deconsolidated on July 14, 2026 upon merger with Glucotrack, Inc.; company received 37,884 Glucotrack common shares and rights to 2,269,100 Series A preferred shares (as converted), measured at $962,935 total fair value; gain on deconsolidation of $7,803,653 recognized in discontinued operations.

    Strategic shift away from biopharmaceutical operations to digital asset focus; BioBusiness results now presented as discontinued operations for all periods.
  • Segment reporting

    Company now operates in one reportable segment (Digital Asset) following disposal of BioBusiness; prior periods restated to show BioBusiness as discontinued operations.

    Company's operations now entirely focused on digital asset holding, trading, and blockchain technology services.
  • Revenue recognition

    First reported revenue from continuing operations: $2.48 million from software development services to two customers, recognized at point in time upon delivery; also $418,899 digital asset yield income from managed bitcoin yield strategy.

    Company generating operating revenue for first time as Digital Asset segment entity.
  • Digital asset yield income presentation

    Digital asset yield income reclassified from other income to revenue beginning Q3 2026; $282,732 for Q2 2026 reclassified; effective April 1, 2026, TechyTrade appointed Calfin Capital as discretionary investment manager for portion of bitcoin holdings.

    Change in financial statement presentation to reflect yield generation as principal ongoing activity.
  • Investment in equity securities

    Investment in Glucotrack of $252,230 as of September 30, 2026, comprising 37,884 common shares ($4,142) and Series A preferred stock rights ($248,088 on as-converted basis), measured at fair value with $710,705 Q3 loss recognized.

    New investment received in exchange for company's 49% interest in Lokahi; subject to Glucotrack stock price volatility.
  • Related party transactions

    New related-party agreements: September 2026, MindWave entered 12-month software development agreement with AQUAE Holdings Pte. Ltd. for $1.112 million plus 20% of ALCI credits; August 2026, FreeT assigned Apitox royalty and revenue participation rights to company with no monetary consideration.

    Company expanding blockchain services with related parties; Apitox rights provide potential future royalty stream.

Primary source

TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.

Open SEC filing

Follow APUS in real time

Get material earnings, filing, IR, and earnings-call alerts by email.

Create a free alert